| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
51,230,000 |
| Market
Cap: |
96.31(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.88 - $1.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
85,987 |
| Total Buy Value |
$0 |
$0 |
$0 |
$85,958 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
124,313 |
| Total Sell Value |
$0 |
$0 |
$0 |
$167,105 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-15 |
4 |
OE |
$0.48 |
$14,400 |
D/D |
30,000 |
170,371 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-08 |
4 |
S |
$7.00 |
$82,712 |
D/D |
(11,816) |
140,371 |
|
-8% |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2021-01-08 |
4 |
S |
$7.00 |
$23,380 |
D/D |
(3,340) |
55,189 |
|
-8% |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2021-01-08 |
4 |
S |
$7.00 |
$19,922 |
D/D |
(2,846) |
71,335 |
|
-8% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-01-08 |
4 |
S |
$7.00 |
$21,910 |
D/D |
(3,130) |
55,881 |
|
-8% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-07 |
4 |
S |
$6.76 |
$68,837 |
D/D |
(10,183) |
152,187 |
|
-16% |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2021-01-07 |
4 |
S |
$6.76 |
$19,462 |
D/D |
(2,879) |
58,529 |
|
-16% |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2021-01-07 |
4 |
S |
$6.76 |
$16,576 |
D/D |
(2,452) |
74,181 |
|
-16% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-01-07 |
4 |
S |
$6.76 |
$18,232 |
D/D |
(2,697) |
59,011 |
|
-16% |
|
| Levin Mark J |
10% Owner |
– – • |
2020-11-19 |
4 |
S |
$7.01 |
$105,075 |
D/D |
(15,000) |
9,200,349 |
|
-52% |
|
| Pfeffer Cary |
Director |
– • – |
2020-11-19 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
|
-52% |
|
| Pfeffer Cary |
Director |
– • – |
2020-11-17 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
|
-38% |
|
| Levin Mark J |
10% Owner |
– – • |
2020-11-17 |
4 |
S |
$7.25 |
$108,773 |
D/D |
(15,000) |
9,215,349 |
|
-38% |
|
| Pfeffer Cary |
Director |
– • – |
2020-11-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(0) |
0 |
|
- |
|
| Levin Mark J |
10% Owner |
– – • |
2020-11-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,000,000) |
9,230,349 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2020-10-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,539,727 |
|
9% |
|
| Duncan Barbara Gayle |
Director |
– • – |
2020-09-15 |
4 |
AS |
$9.50 |
$100,000 |
D/D |
(10,000) |
0 |
|
4% |
|
| Duncan Barbara Gayle |
Director |
– • – |
2020-09-15 |
4 |
OE |
$4.21 |
$42,100 |
D/D |
10,000 |
10,000 |
|
- |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2020-09-01 |
4 |
AS |
$8.06 |
$58,032 |
D/D |
(7,200) |
61,708 |
|
-3% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2020-08-18 |
4 |
S |
$4.71 |
$3,504 |
D/D |
(744) |
68,908 |
|
-40% |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2020-08-18 |
4 |
S |
$4.71 |
$3,504 |
D/D |
(744) |
61,408 |
|
-40% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2020-08-17 |
4 |
S |
$4.86 |
$2,206 |
D/D |
(454) |
69,652 |
|
-31% |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2020-08-17 |
4 |
S |
$4.86 |
$2,206 |
D/D |
(454) |
77,377 |
|
-31% |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2020-08-17 |
4 |
S |
$4.86 |
$2,206 |
D/D |
(454) |
62,152 |
|
-31% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2020-08-14 |
4 |
S |
$4.64 |
$4,566 |
D/D |
(984) |
70,106 |
|
-36% |
|
158 Records found
|
|
Page 4 of 7 |
|
|
